International journal of cancer

publication venue for

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. 2002
T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. 1999
Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancer.. 157. 2025
Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study. 2025
Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.. 155. 2024
Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.. 154. 2023
Incidence and management of esophageal cancer recurrence to regional lymph nodes after curative esophagectomy.. 152. 2023
Immunotherapy with anti-G_D2 monoclonal antibody in infants with high-risk neuroblastoma. 2022
A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma.. 150. 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.. 150. 2021
Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center.. 149. 2021
Contemporary management of breast cancer in Nigeria: Insights from an institutional database.. 148. 2021
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.. 148. 2020
Predictors of mammographic microcalcifications.. 148. 2020
Public health insurance and cancer-specific mortality risk among patients with breast cancer: A prospective cohort study in China.. 148. 2020
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.. 147. 2020
Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women.. 147. 2020
Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.. 147. 2020
A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer.. 146. 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.. 147. 2019
Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.. 147. 2019
The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.. 146. 2019
Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.. 146. 2019
Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx.. 145. 2019
Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus.. 145. 2019
Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up.. 144. 2018
Treatment and outcome of adult-onset neuroblastoma.. 143. 2018
Arsenic promotes the COX2/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells.. 143. 2018
Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks.. 142. 2018
Contralateral breast cancers: Independent cancers or metastases?. 142. 2017
Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study.. 141. 2017
Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence.. 141. 2017
Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study.. 140. 2017
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.. 140. 2016
Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.. 139. 2016
Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies.. 138. 2016
Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects.. 138. 2015
Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.. 138. 2015
Alcohol consumption and risk of breast cancer by molecular subtype: Prospective analysis of the nurses' health study after 26 years of follow-up.. 138. 2015
Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial.. 138. 2015
Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass.. 137. 2015
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.. 137. 2015
A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.. 137. 2015
Assessing individual risk for high-risk colorectal adenoma at first-time screening colonoscopy.. 137. 2015
Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients.. 137. 2014
Inherited variation at MC1R and ASIP and association with melanoma-specific survival.. 136. 2014
The interaction between early-life body size and physical activity on risk of breast cancer.. 137. 2014
SDF-1α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II.. 136. 2014
Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.. 136. 2014
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.. 136. 2014
HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.. 136. 2014
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.. 136. 2014
p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion.. 136. 2014
Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.. 135. 2014
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.. 135. 2014
Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.. 135. 2014
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.. 135. 2014
Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients.. 134. 2013
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.. 133. 2013
Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer.. 133. 2013
Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.. 133. 2013
Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence?. 133. 2013
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.. 131. 2012
Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies.. 131. 2011
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.. 130. 2011
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.. 131. 2011
Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis.. 130. 2011
Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues.. 130. 2011
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.. 128. 2011
Medical radiation exposure and risk of retinoblastoma resulting from new germline RB1 mutation.. 128. 2011
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.. 130. 2011
Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.. 129. 2011
Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.. 129. 2011
Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12.. 128. 2011
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells.. 129. 2010
A strategy for distinguishing optimal cancer subtypes.. 129. 2010
Allergies, obesity, other risk factors and survival from pancreatic cancer.. 127. 2010
Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers.. 127. 2010
Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer.. 127. 2010
Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women.. 127. 2010
A population-based assessment of mortality and morbidity patterns among patients with thymoma.. 128. 2010
Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.. 128. 2010
The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma.. 128. 2010
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors.. 126. 2010
Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma.. 126. 2010
Birth weight and mammographic density among postmenopausal women in Sweden.. 126. 2010
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.. 126. 2010
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease.. 126. 2010
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.. 125. 2009
The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.. 125. 2009
Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer.. 124. 2009
Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs.. 124. 2009
Oviduct-specific glycoprotein is a molecular marker for invasion in endometrial tumorigenesis identified using a relevant mouse model.. 124. 2009
Functional significance of VEGFR-2 on ovarian cancer cells.. 124. 2009
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.. 124. 2009
Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1.. 123. 2008
Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model.. 123. 2008
Variation in lung cancer risk by smoky coal subtype in Xuanwei, China.. 123. 2008
Joint effects of inflammation and androgen metabolism on prostate cancer severity.. 123. 2008
Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer.. 123. 2008
Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.. 123. 2008
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.. 122. 2008
Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial.. 122. 2008
Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts.. 122. 2008
Herpes oncolytic therapy of salivary gland carcinomas.. 122. 2008
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.. 121. 2007
Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries.. 121. 2007
Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma.. 121. 2007
Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.. 121. 2007
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.. 121. 2007
NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration.. 120. 2007
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.. 120. 2007
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.. 119. 2006
Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.. 119. 2006
Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.. 119. 2006
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.. 118. 2006
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.. 118. 2006
Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases.. 118. 2006
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.. 118. 2006
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.. 117. 2005
Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.. 117. 2005
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.. 116. 2005
Reproductive and hormonal factors and risk of brain tumors in adult females.. 114. 2005
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.. 114. 2005
Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase.. 114. 2005
Treatment of aggressive thyroid cancer with an oncolytic herpes virus.. 112. 2004
Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients.. 111. 2004
Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma.. 110. 2004
Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma.. 109. 2004
MSH6 germline mutations are rare in colorectal cancer families.. 107. 2003
Identification of TDE2 gene and its expression in non-small cell lung cancer.. 107. 2003
Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer.. 106. 2003
HER 2/neu expression and gene amplification in colon cancer.. 105. 2003
Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type.. 105. 2003
Cell-free 27 kDa heat shock protein (hsp27) and hsp27-cytochrome c complexes in the cervix of women with ovarian or endometrial cancer.. 102. 2002
The SSX gene family: characterization of 9 complete genes.. 101. 2002
Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma.. 101. 2002
CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues.. 99. 2002
History of allergies and autoimmune diseases and risk of brain tumors in adults.. 99. 2002
Identification of cancer/testis genes by database mining and mRNA expression analysis.. 98. 2002
Optimized intensity-modulated arc therapy for prostate cancer treatment.. 96. 2001
Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.. 94. 2001
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.. 94. 2001
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.. 92. 2001
Interleukin-10 gene promoter polymorphisms in multiple myeloma.. 95. 2001
Protective effect of green tea on the risks of chronic gastritis and stomach cancer.. 92. 2001
IgA antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers.. 87. 2000
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.. 87. 2000
Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.. 87. 2000
Epidemiologic determinants of clinically relevant prostate cancer.. 89. 2000
CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis.. 85. 2000
Expression of MAGE-antigens in normal tissues and cancer.. 85. 2000
High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999).. 83. 1999
Antigens recognized by autologous antibody in patients with renal-cell carcinoma.. 83. 1999
Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8.. 82. 1999
A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn.. 80. 1999
CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons.. 80. 1999
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.. 77. 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.. 77. 1998
Expression of SSX genes in human tumors.. 77. 1998
Characterization of human colon cancer antigens recognized by autologous antibodies.. 76. 1998
Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.. 76. 1998
Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule.. 75. 1998
Adenovirus-mediated gene transfer of fibroblast growth factor-1: angiogenesis and tumorigenicity in nude mice.. 73. 1997
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.. 73. 1997
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens.. 73. 1997
SSX: a multigene family with several members transcribed in normal testis and human cancer.. 72. 1997
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy.. 71. 1997
Chromosome 16 in primary prostate cancer: a microsatellite analysis.. 71. 1997
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.. 70. 1997
Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin.. 67. 1996
Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96.. 69. 1996
MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.. 66. 1996
Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer.. 69. 1996
MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance.. 62. 1995
Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.. 61. 1995
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.. 64. 1995
DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer.. 60. 1995
Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.. 60. 1995
Fibroblast activation protein: purification, epitope mapping and induction by growth factors.. 58. 1994
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.. 58. 1994
p53 mutations in human bladder cancer: genotypic versus phenotypic patterns.. 56. 1994
Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.. 55. 1993
Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.. 54. 1993
A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.. 50. 1992
Neutral glycosphingolipid expression in B-cell neoplasms.. 49. 1991
Monoclonal antibodies against Gal alpha 1-4Gal beta 1-4Glc (Pk, CD77) produced with a synthetic glycoconjugate as immunogen: reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors.. 48. 1991
Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines.. 46. 1990
Maintenance on extracellular matrix and expression of heparanase activity by human ovarian carcinoma cells from biopsy specimens.. 45. 1990
Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML).. 41. 1988
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3.. 39. 1987
Growth of human mammary carcinoma cells from biopsy specimens in serum-free medium on extracellular matrix.. 38. 1986
Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells.. 35. 1985
High-density lipoprotein and extracellular matrix promotes growth and plating efficiency of normal human mammary epithelial cells in serum-free medium.. 31. 1983
The effect of diet on autogenous immunity to mouse mammary tumor virus in C3H/Bi mice.. 26. 1980
Changes in the expression of two Epstein-Barr virus-associated antigens, EBNA and RANA, during the cell cycle of transformed human B lymphoblasts.. 26. 1980
Antibodies reactive with the mouse mammary tumor virus in sera of breast cancer patients.. 25. 1980
Second primary cancers after thymoma.. 107. 2003
Absence of Kaposi's-sarcoma-associated herpesvirus-like DNA sequences (KSHV) in angiosarcomas developing in body-cavity and other sites.. 66. 1996
Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. 2011
Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. 2008
Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. 2005
Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough? 2021
Involvement of autophagy in cervical, endometrial and ovarian cancer. 2013
Vitamin D receptor polymorphisms in patients with cutaneous melanoma. 2011
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. 2006
Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. 2005

VIVO Weill Cornell Medical College

International journal of cancer Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)